Physiologic evidence for high-frequency chest wall oscillation and positive expiratory pressure breathing in hospitalized subjects with cystic fibrosis.

BACKGROUND AND PURPOSE: This investigation identified ventilation distribution, gas mixing, lung function, and arterial blood oxyhemoglobin saturation (SpO(2)) physiologic responses to 2 independent airway clearance treatments, high-frequency chest wall oscillation (HFCWO) and low positive expirator...

Descripción completa

Detalles Bibliográficos
Publicado en:Physical Therapy Vol. 85; no. 12; pp. 1278 - 1290
Autores principales: Darbee JC, Kanga JF, Ohtake PJ
Formato: pictorial research tables/charts Journal Article
Publicado: Oxford University Press / USA Dec2006
Acceso en línea:Ver este registro en EBSCOhost
Descripción
Sumario:BACKGROUND AND PURPOSE: This investigation identified ventilation distribution, gas mixing, lung function, and arterial blood oxyhemoglobin saturation (SpO(2)) physiologic responses to 2 independent airway clearance treatments, high-frequency chest wall oscillation (HFCWO) and low positive expiratory pressure (PEP) breathing, for subjects who had cystic fibrosis (CF) and who were hospitalized during acute and subacute phases of a pulmonary exacerbation. SUBJECTS: Fifteen subjects with moderate to severe CF were included in this study. METHODS: Subjects performed single-breath inert gas tests and spirometry before and immediately after HFCWO and PEP breathing at admission and discharge. Arterial blood oxyhemoglobin saturation was monitored throughout each treatment. RESULTS: At admission and discharge, PEP breathing increased SpO(2) during treatment, whereas HFCWO decreased SpO(2) during treatment. Ventilation distribution, gas mixing, and lung function improved after HFCWO or PEP breathing. DISCUSSION AND CONCLUSION: High-frequency chest wall oscillation and PEP breathing are similarly efficacious in improving ventilation distribution, gas mixing, and pulmonary function in hospitalized people with CF. Because SpO(2) decreases during HFCWO, people who have moderate to severe CF and who use HFCWO should have SpO(2) monitored during an acute exacerbation.